



Biotech Daily

Friday January 21, 2022

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: PRO MEDICUS UP 0.1%; CYNATA DOWN 9%**
- * **COGSTATE H1 REVENUE UP 67% TO \$29.6m**
- * **GENETIC SIGNATURES H1 REVENUE UP 16% TO \$22m**
- * **HERAMED: \$220k JOONDALUP HERACARE CONTRACT**
- * **TRAJAN FOUNDER STEPHEN TOMISICH, FAMILY DILUTED TO 57%**
- * **IMUGENE LOSES CMO DR RITA LAEUFLE**

MARKET REPORT

The Australian stock market tumbled 2.27 percent on Friday January 21, 2022, with the ASX200 down 166.6 points to 7,175.8 points.

Just one of the Biotech Daily Top 40 stocks was up, 33 fell, five traded unchanged and one was untraded. All three Big Caps fell.

Pro Medicus was the only BDI-40 to climb, up five cents or 0.1 percent to \$45.38, with 397,580 shares traded.

Cynata led the falls, down five cents or 9.3 percent to 49 cents, with 110,689 shares traded.

Actinogen and Genetic Signatures fell more than seven percent; Atomo, Clinuvel, Cyclopharm, Immutep, Imugene and Prescient lost more than six percent; Amplia, Impedimed, Kazia, Mesoblast, Orthocell, Paradigm, Patrys, Polynovo and Universal Biosensors fell more than five percent; Avita, Neuren and Pharmaxis fell four percent or more; Micro-X, Nanosonics, Nova Eye, Opthea, Starpharma and Volpara were down more than three percent; Antisense, CSL, Emvision and Medical Developments shed more than two percent; with Alcidion, Cochlear, Dimerix, Next Science and Resmed down by more than one percent.

COGSTATE

Cogstate says revenue for the six months to December 31, 2021 was up 67 percent to \$US21.3 million (A\$29.6 million), compared to the previous corresponding period. Cogstate said receipts from customers and “pass-through receipts” for the same period were down 23.4 percent to \$US22,600,071.

The company said that revenue came from clinical trial sales contracts and deferred revenue from its licencing agreement with Eisai, for its cognition testing systems. The company said it was \$US1,549,428 cashflow positive for the three months to December 31, 2021, with cash and cash equivalents of \$US25,336,663 at December 31, 2021 compared to \$US21,329,622 at December 31, 2020. Cogstate fell 37 cents or 15.95 percent to \$1.95 with 1.5 million shares traded.

GENETIC SIGNATURES

Genetic Signatures says revenue for the six months to December 31, 2021 was up 16 percent to \$21.8 million, compared to the previous corresponding period. Genetic Signatures said that receipts from customers for the six months to December 31, 2021 were up 10.4 percent to \$22,424,000. Genetic Signatures chief executive officer Dr John Melki said that revenue came from “continued and strong demand for our 3base Easyscreen Sars-Cov-2 detection kits”. The company said it was \$4,835,000 cashflow positive for the three months to December 31, 2021, with cash and cash equivalents of \$37,496,000 at December 31, 2021 compared to \$36,273,000 at December 31, 2020. Genetic Signatures fell 12 cents or 7.7 percent to \$1.44.

HERAMED

Heramed says it has a \$220,000 contract with Perth’s Joondalup Health Campus to use its Heracare foetal monitors “as the primary standard-of-care” for expectant mothers. Heramed said the 12-month contract with Joondalup was the first signed with a major healthcare provider and had an option to extend for a further three years. Heramed chief executive officer and founder David Groberman said the contract was “a truly significant milestone for Heramed”. Mr Groberman said the agreement showed “that our strategy of delivering clinical validation of the Heracare platform, which led to a successful paid pilot [program], provided the correct foundation for broader commercial rollout of Heracare within the hospital”. Heramed fell half a cent or 1.7 percent to 28.5 cents with 1.9 million shares traded.

TRAJAN

Trajan founder Stephen Tomisich and his family say their 76,470,588 share-holding has been diluted from 59.03 percent to 56.82 percent. The Tomisich family said the dilution followed “various share issues”. Trajan fell 12 cents or 2.7 percent to \$4.33.

IMUGENE

Imugene says its chief medical officer Dr Rita Laeufle will retire from her role at the end of January 2022.

Imugene managing-director Leslie Chong thanked Dr Laeufle “for her valuable contribution over the past 16 months and wish her well in her retirement”.

The company said it was “in the final negotiation to bring in a high calibre oncologist and clinical developer” as a chief medical officer”.

Imugene fell 2.5 cents or 6.9 percent to 33.5 cents with 59.7 million shares traded.